CliffBio
small molecule

TREZIX

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

Loss of exclusivity—loss of exclusivity
CompanyKEY THERAPEUTICS LLC

Drug detail

Brand nameTREZIX
Active ingredientACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
Strength320.5MG;30MG;16MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2014
Marketing statusDISCN

More from KEY THERAPEUTICS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TREZIX patent cliff — loss of exclusivity — | CliffBio